Institution
Sunovion
Company•London, United Kingdom•
About: Sunovion is a company organization based out in London, United Kingdom. It is known for research contribution in the topics: Lurasidone & Placebo. The organization has 572 authors who have published 1022 publications receiving 18488 citations. The organization is also known as: Sunovion Pharmaceuticals, Inc..
Topics: Lurasidone, Placebo, Population, Eszopiclone, Atypical antipsychotic
Papers published on a yearly basis
Papers
More filters
•
31 May 1995TL;DR: In this paper, the optically pure (S)-isomer of lomefloxacin was used to treat bacterial infection and was shown to be a potent drug for the treatment of Mycobacteria infection.
Abstract: Methods and compositions are disclosed utilizing the optically pure (S)-isomer of lomefloxacin to treat bacterial infection. In particular, this compound is a potent drug for the treatment of Mycobacteria infection.
3 citations
••
TL;DR: Findings support the potential utility of the ATCQ questionnaire in quantifying antipsychotic prescribing decisions and suggest that predictions of symptom control and metabolic risk correlated significantly with antipsychotics choice, but study psychiatrists were willing to assume relative degrees of metabolic risk in favor of effective symptom control.
Abstract: Background Evidence on antipsychotic prescribing decisions is limited. This pilot study quantified factors considered in choosing an antipsychotic and evaluated the influence of metabolic status on treatment decisions. Methods Prescribing decisions by 4 psychiatrists were examined based on 80 adult patients initiated on antipsychotic medication diagnosed with schizophrenia, schizoaffective disorder or bipolar disorder by DSM-IV criteria, who were admitted to an acute inpatient psychiatric program of an urban Veterans Affairs Medical Center. The primary analysis examined the association between antipsychotic treatment choice and predictions of symptom control and metabolic risk. Secondary analyses included comparison of the chosen and next best treatments in predicted symptom control and metabolic risk, the frequency of reasons cited for drug choice, and the association between treatment choice and patients' baseline metabolic parameters. Mean differences and odds-ratios (OR) with 95% confidence intervals were used to compare relationships between treatment choice, ratings of risk and metabolic data. Results Antipsychotic choice correlated significantly with ratings of predicted symptom control (OR = .92, p = 0.02) and metabolic risk (OR = .88, p = 0.01). Mean differences between the chosen and next best drugs were significant but small in predicted symptom control (F = 2.81, df = 3, 76; p Conclusion In the context of an acute psychiatric hospitalization, pilot data suggest that predictions of symptom control and metabolic risk correlated significantly with antipsychotic choice, but study psychiatrists were willing to assume relative degrees of metabolic risk in favor of effective symptom control. However, prescribing decisions were influenced by numerous patient and treatment factors. These findings support the potential utility of the ATCQ questionnaire in quantifying antipsychotic prescribing decisions. Further validation studies of the ATCQ questionnaire could enhance translation of research findings and application of treatment guidelines.
3 citations
••
TL;DR: The results of this post-hoc analysis suggest that long-term treatment with ESL was effective and well tolerated, both as a monotherapy and in combination with other AEDs for FS.
3 citations
••
TL;DR: Ezopiclone/fluoxetine co-therapy resulted in significant improvements in the insomnia items of the HAMD17, and several items related to core depressive symptoms were also improved with co-Therapy compared with monotherapy.
3 citations
••
TL;DR: A series of novel tetrahydroquinoline amines that potently inhibit the in vitro reuptake of serotonin and dopamine are described, which represent a previously undisclosed dual reuptakes inhibitor chemotype.
3 citations
Authors
Showing all 572 results
Name | H-index | Papers | Citations |
---|---|---|---|
Chris H. Senanayake | 58 | 588 | 12142 |
Paul J. Reider | 55 | 344 | 9827 |
Antony Loebel | 42 | 223 | 6906 |
Kenneth S. Koblan | 40 | 96 | 4380 |
Richard G. Ball | 37 | 142 | 3684 |
Robert D. Larsen | 36 | 147 | 3544 |
Robert Goldman | 35 | 110 | 7064 |
Raymond L. Woosley | 34 | 115 | 3811 |
Rudy Schreiber | 33 | 80 | 3793 |
Thomas R. Verhoeven | 29 | 127 | 3135 |
Andrei Pikalov | 28 | 120 | 2583 |
David Blum | 27 | 89 | 2958 |
Mark A. Varney | 26 | 41 | 4032 |
Lisa DiMichele | 25 | 88 | 1755 |
John P. Hanrahan | 25 | 46 | 2781 |